FDA — authorised 22 March 2016
- Application: BLA125521
- Marketing authorisation holder: ELI LILLY AND CO
- Local brand name: TALTZ
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Proactive TDM-based dosing of ixekizumab in United States
FDA authorised Proactive TDM-based dosing of ixekizumab on 22 March 2016
Marketing authorisation
Proactive TDM-based dosing of ixekizumab in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Proactive TDM-based dosing of ixekizumab approved in United States?
Yes. FDA authorised it on 22 March 2016.
Who is the marketing authorisation holder for Proactive TDM-based dosing of ixekizumab in United States?
ELI LILLY AND CO holds the US marketing authorisation.